Inhibitory effects of PI3K/AKT inhibitor LY294002 on retinal neovascularization in mice
10.13389/j.cnki.rao.2018.0048
- VernacularTitle:磷脂酰肌醇-3-激酶/丝氨酸-苏氨酸激酶抑制剂LY294002对小鼠视网膜新生血管形成的抑制作用
- Author:
Yu DI
1
;
Xiao-Long CHEN
Author Information
1. 中国医科大学附属盛京医院眼科
- Keywords:
LY294002;
phosphatidylinositol-3-kinase/serine/threonine kinase;
oxygen-induced retinopathy;
retinopathy of prematurity;
retinal neovascularization
- From:
Recent Advances in Ophthalmology
2018;38(3):210-213
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the effects of phosphatidylinositol-3-kinase (PI3K)/serine-threonine kinase (AKT) signal pathway inhibitor LY294002 on retinal neovascularization (RNV) in oxygen-induced retinopathy (OIR) mice.Methods Totally 60 C57BL/6J mice were collected and randomly divided into the experimental group and control group,with 30 mice in each group.Then OIR model was induced by Smith methods.Rats in the experimental group were intravitreally injected with 0.5 μL LY294002,while the control group was given the same amount of phosphate buffer saline (PBS) one day before out of the incubator.Retinal sections with HE staining were applied to count the number of neovascular cell nuclei breaking through the inner limiting membrane,as well as the protein and mRNA expression of pAKT and vascular endothelial growth factor (VEGF) were detected by immunohistochemistry and RT-PCR.Results The number of retinal neovascular cell nucleus in the experimental group was obviously smaller than that in the control group (P ＜ 0.05).The protein expression of pAKT and VEGF was weakly expressed,and the absorbance (A) value of the positive cells was decreased in the experimental group compared with the control group (all P ＜ 0.05).The mRNA expression of AKT and VEGF was obviously decreased in the experimental group compared with the control group (all P ＜ 0.05).Conclusion The development of RNV in OIR mice can be markedly inhibited by LY294002 inhibiting PI3K/AKT pathway,and therefore LY294002 is expected to be an effective method for preventing vascular proliferative retinopathy.
